Related Experiment Video
Updated: Sep 28, 2025
Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Multisystem inflammatory syndrome in children (MIS-C) possibly secondary to COVID-19 mRNA vaccination
Zoon Wangu1,2, Hannah Swartz3, Meaghan Doherty4
1Pediatric Infectious Diseases & Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA zoon.wangu@umassmemorial.org.
Insights
Multisystem inflammatory syndrome in children (MIS-C) may rarely occur after COVID-19 vaccination. This case report suggests vaccination could be a potential trigger in individuals without prior infection.
Area of Science:
- Immunology
- Pediatric Infectious Diseases
- Vaccinology
Background:
- Multisystem inflammatory syndrome in children (MIS-C) is a rare postinfectious complication of SARS-CoV-2 infection.
- The precise pathogenesis of MIS-C remains incompletely understood.
- Concerns exist regarding potential MIS-C development following COVID-19 vaccination.
Observation:
- A case of MIS-C is presented in an adolescent female.
- The patient received two doses of the Pfizer-BioNTech COVID-19 vaccine 12 weeks prior to symptom onset.
- She had no documented SARS-CoV-2 infection history, with negative PCR tests and specific antibody profiles (anti-spike IgG positive, antinucleocapsid IgG negative).
Findings:
- The patient developed MIS-C following COVID-19 vaccination.
- This case suggests a potential, albeit rare, association between COVID-19 vaccination and MIS-C development.
- The findings highlight the need to consider vaccination as a potential trigger in the absence of infection.
Implications:
- COVID-19 vaccination is crucial for pandemic control and remains safe for the vast majority.
- Further surveillance is warranted to investigate the potential link between COVID-19 vaccination and MIS-C.
- This case contributes to understanding the diverse clinical presentations and potential triggers of MIS-C.
Abstract:
Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 is a postinfectious condition identified during the COVID-19 pandemic with specific Centers for Disease Control and Prevention and WHO criteria. Theoretical concerns have been raised whether MIS-C might also occur after COVID-19 vaccination, as the pathogenesis of MIS-C is not yet entirely understood. We present a woman in her late teens who developed MIS-C after having received two doses of Pfizer BioNTech COVID-19 vaccine 12 weeks prior, in the setting of documented anti-spike SARS-CoV-2 IgG positive, antinucleocapsid SARS-CoV-2 IgG negative, and multiple negative surveillance SARS-CoV-2 PCRs done in the 12-week period prior to development of MIS-C. While vaccination remains safe and critical in controlling the pandemic, it may be considered as a potential trigger for MIS-C in patients with no history of infection. Further surveillance is necessary to determine whether MIS-C will emerge as a confirmed adverse event after COVID-19 vaccination.
More Related Videos
08:44Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
08:10Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
Published on: November 28, 2018
Related Concept Videos
01:51Vaccinations
01:14Myocarditis III: Medical Management
01:27Myocarditis II: Clinical Features and Diagnostic Tests